Avasopasem manganese

DB16354InvestigationalSmall molecule

Avasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis. This drug has potential...

Mechanism: Avasopasem manganese is a superoxide dismutase mimetic that rapidly and selectively converts superoxide to hydrogen peroxide and oxygen in order to protect normal tissue from radiation therapy-induced damage. This drug is currently being investigated against oral mucositis, esophagitis, and COVID-19.
Curator reviewed · 1 reference
Formula / weight: C₂₁H₃₅Cl₃MnN₅ · 518.83 g/mol (avg)
Code names: GC-4419 · M-40419 · SC-72325A

Resolves to

Compound

UNIIEY1WA413ULCAS435327-40-5

Structure

InChIKeyWXEMWBBXVXHEPU-NDOCQCNASA-LSMILES[Cl-].[Cl-].[Mn++].C1CC[C@@H]2NCC3=CC=CC(CN[C@H]4CCCC[C@@H]4NCCN[C@H]2C1)=N3

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which companies are running trials of Avasopasem manganese, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account